MYE
0.455
33.8%
PEN
0.277
-24.1%
ARV
0.004
33.3%
ADX
0.019
-20.8%
MRQ
0.004
33.3%
HTG
0.01
-16.7%
CMD
0.029
31.8%
RGT
0.046
-14.8%
PIQ
0.195
30%
IDT
0.035
-14.6%
AUA
0.038
26.7%
VBS
0.15
-14.3%
EVR
0.005
25%
SLD
0.452
-13.9%
AMD
0.006
20%
HFR
0.019
-13.6%
MML
0.012
20%
CCA
0.055
-12.7%
WEC
0.18
20%
M96
0.007
-12.5%
IFN
0.465
19.2%
PLC
0.007
-12.5%
LUX
0.32
18.5%
RWD
0.03
-11.8%
DBO
0.013
18.2%
MEK
0.093
-11.4%
NRX
0.013
18.2%
APC
0.008
-11.1%
CCE
0.235
17.5%
ATC
0.008
-11.1%
FCT
0.007
16.7%
CDE
0.008
-11.1%
AT4
0.036
16.1%
HIQ
0.008
-11.1%
KLI
0.18
16.1%
PPY
0.008
-11.1%
HMG
0.145
16%
AGR
0.017
-10.5%
ABV
0.11
15.8%
AT1
0.017
-10.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics has successfully manufactured and passed quality release testing

Arovella Therapeutics (ASX:ALA) has successfully manufactured and passed quality release testing for its lead product ALA-101 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240102/pdf/05z33l2t26k412.pdf #ALA #Cancer